Benefit from anthracyclines in relation to biological profiles in early breast cancer-Reference-Cited by-同舟云学术

Benefit from anthracyclines in relation to biological profiles in early breast cancer

Published:2014-01-01 Issue:2 Volume:144 Page:307-318
ISSN:0167-6806
Container-title:Breast Cancer Research and Treatment
language:en
Short-container-title:Breast Cancer Res Treat

Author:

Rocca Andrea,Bravaccini Sara,Scarpi Emanuela,Mangia Anita,Petroni Stella,Puccetti Maurizio,Medri Laura,Serra Luigi,Ricci Monica,Cerasoli Serenella,Biglia Nicoletta,Maltoni Roberta,Giunchi Donata Casadei,Gianni Lorenzo,Tienghi Amelia,Brandi Mario,Faedi Monica,Sismondi Piero,Paradiso Angelo,Silvestrini Rosella,Amadori Dino

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology

Link

http://link.springer.com/content/pdf/10.1007/s10549-013-2819-0.pdf

Reference25 articles.

1. Early Breast Cancer Trialists’ Collaborative Group (EBCTCG), Peto R, Davies C, Godwin J, Gray R, Pan HC, Clarke M, Cutter D, Darby S, McGale P, Taylor C, Wang YC, Bergh J, Di Leo A, Albain K, Swain S, Piccart M, Pritchard K (2012) Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials. Lancet 379(9814):432–444. doi: 10.1016/S0140-6736(11)61625-5

2. Munro AF, Cameron DA, Bartlett JM (2010) Targeting anthracyclines in early breast cancer: new candidate predictive biomarkers emerge. Oncogene 29(38):5231–5240. doi: 10.1038/onc.2010.286

3. Gennari A, Sormani MP, Pronzato P, Puntoni M, Colozza M, Pfeffer U, Bruzzi P (2008) HER2 status and efficacy of adjuvant anthracyclines in early breast cancer: a pooled analysis of randomized trials. J Natl Cancer Inst 100(1):14–20

4. Di Leo A, Desmedt C, Bartlett JM, Piette F, Ejlertsen B, Pritchard KI, Larsimont D, Poole C, Isola J, Earl H, Mouridsen H, O’Malley FP, Cardoso F, Tanner M, Munro A, Twelves CJ, Sotiriou C, Shepherd L, Cameron D, Piccart MJ, Buyse M, HER2/TOP2A Meta-analysis Study Group (2011) HER2 and TOP2A as predictive markers for anthracycline-containing chemotherapy regimens as adjuvant treatment of breast cancer: a meta-analysis of individual patient data. Lancet Oncol 12(12):1134–1142. doi: 10.1016/S1470-2045(11)70231-5

5. Gianni L, Norton L, Wolmark N, Suter TM, Bonadonna G, Hortobagyi GN (2009) Role of anthracyclines in the treatment of early breast cancer. J Clin Oncol 27(28):4798–4808. doi: 10.1200/JCO.2008.21.4791

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The impact of progesterone receptor expression on prognosis of patients with rapidly proliferating, hormone receptor-positive early breast cancer: a post hoc analysis of the IBIS 3 trial;Therapeutic Advances in Medical Oncology;2020-01

2. Adjuvant Systemic Chemotherapy for HER2-Negative Disease;Breast Disease;2019

3. Real-life clinical pattern, management, and survival in Thai patients with early-stage or metastatic triple-negative breast cancer;PLOS ONE;2018-12-19

4. Herceptin® (trastuzumab) in HER2-positive early breast cancer: a systematic review and cumulative network meta-analysis;Systematic Reviews;2018-11-14

5. Is Ki67 still a powerful ally in predicting the clinical benefit of anthracyclines for the adjuvant treatment of early breast cancer?;Breast Cancer Research and Treatment;2018-01-06